Folate receptor-mediated drug targeting: from therapeutics to diagnostics.

By A. Hilgenbrink, P. Low. Journal of Pharmacy and Science, 2005

637 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/316cf3df4df2bb5ca06304e44a630fb40f165965

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Stephanie D. Steichen
2. Mary E. Caldorera-Moore
3. P. Couvreur
4. Nicholas A. Peppas

In Hematology

1. Stephanie D. Steichen
2. Mary E. Caldorera-Moore
3. Nicholas A. Peppas

In Public Health, Environmental and Occupational Health

1. Stephanie D. Steichen
2. Mary E. Caldorera-Moore
3. Nicholas A. Peppas

Citations in the corpus

• Nanocarriers’ entry into the cell: relevance to drug delivery (2009, background): “Indeed, FA binds with a low affinity to the reduced folate carrier present in virtually all cells, but with a high affinity (in the nanomolar range) to the glycosylphosphatidylinositol-linked folate receptor (FR), which exhibits highly limited distribution [129].”
• A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics (2012, positive): “The folate receptor (FR), or the high affinity membrane folate binding protein, binds the folate molecule with extremely high affinity (KD~10−9) (Gu et al., 2007; Hilgenbrink and Low, 2005).”
• Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy. (2011, background): “Folate receptor is a widely studied cancer cell marker that up-regulated in many types of cancer cell [33,34].”
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Folates have been widely utilized because of their very high affinity (KD = ~10-9 M) and specificity for folate receptors (FR) which are frequently over-expressed on the surface of a variety of human tumors, including ovarian, brain, breast, colon, renal and lung cancers [293, 294].”
• Cancer active targeting by nanoparticles: a comprehensive review of literature (2014, background): “On the other hand, it is consistently expressed in specific types of major malignant tumors and leukemic cells making them accessible to the targeted nanoparticles via the circulation, thereby eliminating nonspecific targeting and minimizing toxicity (Hilgenbrink and Low 2005; Elnakat and Ratnam 200”